In vivo infectivity of liver extracts after resolution of hepadnaviral infection following therapy associating DNA vaccine and cytokine genes

Journal of Viral Hepatitis

Volumn 20, Issue 4, 2013, Pages

  Saade, F ^a,b   Buronfosse, T ^a,b,c   Guerret, S ^d   Pradat, P ^e   Chevallier, M ^f   Zoulim, F ^a,b,e   Jamard, C ^a,b   Cova, L ^a,b  

^a UNIVERSITÉ DE LYON   (France)

^b CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^c VETAGRO SUP   (France)

^d Novotec   (France)

^e CROIX ROUSSE HOSPITAL   (France)

^f Laboratoire Mérieux   (France)

Author keywords

chronic hepatitis B; DHBV; DNA vaccine; HBV; IFN ; IL 2; occult hepatitis B; viral persistence

Indexed keywords

CORE PROTEIN; DNA VACCINE; GAMMA INTERFERON; INTERLEUKIN 2; LIVER EXTRACT; VIRUS DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE TRANSMISSION; DNA IMMUNIZATION; DUCK HEPATITIS B VIRUS; FOLLOW UP; HEPADNAVIRUS INFECTION; HEPATITIS B; IMMUNOTHERAPY; IN VIVO STUDY; INFECTION PREVENTION; LIVER CELL; LIVER HOMOGENATE; LIVER NECROSIS; NEWBORN; NONHUMAN; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIREMIA; VIRUS DETECTION; VIRUS REPLICATION;

ANIMALS; CARRIER STATE; DNA, VIRAL; DUCKS; FOLLOW-UP STUDIES; HEPADNAVIRIDAE INFECTIONS; HEPATITIS B VACCINES; HEPATITIS B VIRUS, DUCK; HEPATITIS, VIRAL, ANIMAL; INTERFERON-GAMMA; INTERLEUKIN-2; LIVER; VACCINES, DNA; VIRAL LOAD; VIREMIA;

EID: 84875214391     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12023     Document Type: Article

References (42)

1. Lavanchy D,. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11 (2): 97-107.
2. Rehermann B,. Chronic infections with hepatotropic viruses: mechanisms of impairment of cellular immune responses. Semin Liver Dis 2007; 27 (2): 152-160.
3. Michel ML, Tiollais P,. Hepatitis B vaccines: protective efficacy and therapeutic potential. Pathol-Biol [Review] 2010; 58 (4): 288-295.
4. Michel ML, Deng Q, Mancini-Bourgine M,. Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges. J Hepatol [Review] 2011; 54 (6): 1286-1296.
5. Cova L,. Progress in DNA vaccination against HBV infection. Future Virol 2012; 7 (2): 149-160.
6. Mancini M, Hadchouel M, Davis HL, Whalen RG, Tiollais P, Michel ML,. DNA-mediated immunization in a transgenic mouse model of the hepatitis B surface antigen chronic carrier state. Proc Natl Acad Sci 1996; 93 (22): 12496-12501.
7. Mancini-Bourgine M, Fontaine H, Scott-Algara D, Pol S, Brechot C, Michel ML,. Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers. Hepatology 2004; 40 (4): 874-882.
8. Yang SH, Lee CG, Park SH, et al,. Correlation of antiviral T-cell responses with suppression of viral rebound in chronic hepatitis B carriers: a proof-of-concept study. Gene Ther 2006; 13 (14): 1110-1117.
9. Cavenaugh JS, Awi D, Mendy M, Hill AV, Whittle H, McConkey SJ,. Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection. PLoS ONE 2011; 6 (2): 14626-14632.
10. Fontaine HCC, Mancini-Bourgine M,. Relapse after analogues treatment discontinuation is not prevented by DNA vaccination in chronic hepatitis B. J Hepatol 2012; 56: S150.
11. Saade F, Petrovsky N,. Technologies for enhanced efficacy of DNA vaccines. Expert Rev Vaccines 2012; 11 (2): 189-209.
12. Chow YH, Chiang BL, Lee YL, et al,. Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes. J Immunol 1998; 160 (3): 1320-1329.
13. Siegel F, Lu M, Roggendorf M,. Coadministration of gamma interferon with DNA vaccine expressing woodchuck hepatitis virus (WHV) core antigen enhances the specific immune response and protects against WHV infection. J Virol 2001; 75 (11): 5036-5042.
14. Wang J, Gujar SA, Cova L, Michalak TI,. Bicistronic woodchuck hepatitis virus core and gamma interferon DNA vaccine can protect from hepatitis but does not elicit sterilizing antiviral immunity. J Virol 2007; 81 (2): 903-916.
15. Roggendorf M, Yang D, Lu M,. The woodchuck: a model for therapeutic vaccination against hepadnaviral infection. Pathol Biol [Review] 2010; 58 (4): 308-314.
16. Michalak TI, Pasquinelli C, Guilhot S, Chisari FV,. Hepatitis B virus persistence after recovery from acute viral hepatitis. J Clin Invest 1994; 94 (2): 907.
17. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV,. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996; 2 (10): 1104-1108.
18. Marusawa H, Uemoto S, Hijikata M, et al,. Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. Hepatology 2000; 31 (2): 488-495.
19. Michalak TI, Pardoe IU, Coffin CS, et al,. Occult lifelong persistence of infectious hepadnavirus and residual liver inflammation in woodchucks convalescent from acute viral hepatitis. Hepatology 1999; 29 (3): 928-938.
20. Rollier C, Sunyach C, Barraud L, et al,. Protective and therapeutic effect of DNA-based immunization against hepadnavirus large envelope protein. Gastroenterology 1999; 116 (3): 658-665.
21. Le Guerhier F, Thermet A, Guerret S, et al,. Antiviral effect of adefovir in combination with a DNA vaccine in the duck hepatitis B virus infection model. J Hepatol 2003; 38 (3): 328-334.
22. Thermet A, Buronfosse T, Werle-Lapostolle B, et al,. DNA vaccination in combination or not with lamivudine treatment breaks humoral immune tolerance and enhances cccDNA clearance in the duck model of chronic hepatitis B virus infection. J Gen Virol 2008; 89 (Pt 5): 1192-1201.
23. Cova L, Zoulim F,. Duck hepatitis B virus model in the study of hepatitis B virus. Methods Mol Med 2004; 96: 261-268.
24. Saade F, Buronfosse T, Pradat P, Abdul F, Cova L,. Enhancement of neutralizing humoral response of DNA vaccine against duck hepatitis B virus envelope protein by co-delivery of cytokine genes. Vaccine 2008; 26 (40): 5159-5164.
25. Mandart E, Kay A, Galibert F,. Nucleotide sequence of a cloned duck hepatitis B virus genome: comparison with woodchuck and human hepatitis B virus sequences. J Virol 1984; 49 (3): 782-792.
26. Thermet A, Robaczewska M, Rollier C, et al,. Identification of antigenic regions of duck hepatitis B virus core protein with antibodies elicited by DNA immunization and chronic infection. J Virol 2004; 78 (4): 1945-1953.
27. Narayan R, Buronfosse T, Schultz U, et al,. Rise in gamma interferon expression during resolution of duck hepatitis B virus infection. J Gen Virol 2006; 87 (Pt 11): 3225-3232.
28. Zhang YY, Theele DP, Summers J,. Age-related differences in amplification of covalently closed circular DNA at early times after duck hepatitis B virus infection of ducks. J Virol 2005; 79 (15): 9896-9903.
29. Barraud L, Guerret S, Chevallier M, et al,. Enhanced duck hepatitis B virus gene expression following aflatoxin B1 exposure. Hepatology 1999; 29 (4): 1317-1323.
30. Jilbert AR, Miller DS, Scougall CA, Turnbull H, Burrell CJ,. Kinetics of duck hepatitis B virus infection following low dose virus inoculation: one virus DNA genome is infectious in neonatal ducks. Virology 1996; 226 (2): 338-345.
31. Cova L, Wild CP, Mehrotra R, et al,. Contribution of aflatoxin B1 and hepatitis B virus infection in the induction of liver tumors in ducks. Canc Res 1990; 50 (7): 2156-2163.
32. Le Guerhier F, Pichoud C, Guerret S, et al,. Characterization of the antiviral effect of 2',3'-dideoxy-2', 3'-didehydro-beta-L-5-fluorocytidine in the duck hepatitis B virus infection model. Antimicrob Agents Chemother 2000; 44 (1): 111-122.
33. Foster WK, Miller DS, Marion PL, Colonno RJ, Kotlarski I, Jilbert AR,. Entecavir therapy combined with DNA vaccination for persistent duck hepatitis B virus infection. Antimicrob Agents Chemother 2003; 47 (8): 2624-2635.
34. Le Mire MF, Miller DS, Foster WK, Burrell CJ, Jilbert AR,. Covalently closed circular DNA is the predominant form of duck hepatitis B virus DNA that persists following transient infection. J Virol 2005; 79 (19): 12242-12252.
35. Reaiche GY, Le Mire MF, Mason WS, Jilbert AR,. The persistence in the liver of residual duck hepatitis B virus covalently closed circular DNA is not dependent upon new viral DNA synthesis. Virology 2010; 406 (2): 286-292.
36. Raimondo G, Pollicino T, Romano L, Zanetti AR,. A 2010 update on occult hepatitis B infection. Pathol Biol [Review] 2010; 58 (4): 254-257.
37. Hollinger FB, Sood G,. Occult hepatitis B virus infection: a covert operation. J Viral Hepat 2010; 17 (1): 1-15.
38. Menne S, Cote PJ, Butler SD, Toshkov IA, Gerin JL, Tennant BC,. Immunosuppression reactivates viral replication long after resolution of woodchuck hepatitis virus infection. Hepatology 2007; 45 (3): 614-622.
39. Bruch HR, Korn A, Klein H, et al,. Treatment of chronic hepatitis B with interferon alpha-2b and interleukin-2. J Hepatol 1993; 17 (Suppl 3): S52-S55.
40. Asabe S, Wieland SF, Chattopadhyay PK, et al,. The size of the viral inoculum contributes to the outcome of hepatitis B virus infection. J Virol 2009; 83 (19): 9652-9662.
41. Chemin I, Trépo C,. Clinical impact of occult HBV infections. J Clin Virol 2005; 34 (1): 15-21.
42. Blum HE, Offesperger WB, Walter E, Offensperger S, Gerok W,. Latent hepatitis B virus infection with full-length viral genome in a patient serologically immune to hepatitis B virus infection. Liver 1988; 8 (5): 307-316.